Entries by gatekeeper

Emergex appoints US Federal Government experts The Conafay Group

Oxford, UK, 13 July 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has appointed The Conafay Group, US Federal Government experts, to advise on the US healthcare landscape and policy and to provide introductions to help […]

Emergex Files a Patent in the USA for its novel Pandemic Flu Vaccine

Oxford, UK, 24 May 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to enable synthetic vaccine development in the field of infectious diseases, today announces that it has filed a patent in the USA for its novel pandemic flu vaccine. The patent, entitled, ‘Reverse Peptide Vaccines’ covers the use […]

Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu Vaccine

Oxford, UK, 14 May 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development. This […]

Sir David King Joins Emergex’s Board of Directors

Oxford, UK, 29 March 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Sir David King has joined Emergex’s Board as a Non-Executive Director. David is an Affiliate Partner of SYSTEMIQ, the corporate and government sustainability advisory firm […]

Emergex Builds its Finance Team with Two New Recruits

Oxford, UK, 28 March 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has built its Finance team and strengthening its operational capabilities. Alex Bronimann joins Emergex as Finance Director. He brings over 20 years’ experience in […]

Emergex Progresses its Synthetic Vaccine Development Pipeline

Pioneering a simple, inexpensive and fast approach to vaccine development using 100% synthetic vaccine constructs to provide long-lasting cellular immunity against infections Lead vaccine candidates have been identified for our universal Flavivirus (Dengue, Zika, Yellow Fever), universal Filovirus (Ebola) and Pandemic/universal Influenza virus programmes Dengue, Ebola and Zika vaccines are all approaching clinical development, with […]

Emergex Vaccines awarded SBRI contract by Innovate UK

Oxford, UK, 5 April 2017 – Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that they have been awarded a £499,825 SBRI contract with the Department of Health/Technology Strategy Board, facilitated by Innovate UK, the UK’s Innovation Agency. The […]

Emergex Vaccines approved as member of the Social Stock Exchange

Oxford, UK, 20 February 2017 – Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announces that they have been approved as a member of the Social Stock Exchange, society’s market for impact investing. This follows the ratification of Emergex’s impact […]

Emergex Vaccines provides an update on Agreement with Midatech Pharma

Oxford, UK, 22 November 2016 – Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that it has paid an upfront technology access fee and option payment of £450,000 to Midatech Pharma (AIM: MTPH, NASDAQ: MTP), under the terms of […]